What Is ARFID?
Avoidant/Restrictive Food Intake Disorder (ARFID) is a feeding or eating disturbance that results in a persistent failure to meet appropriate nutritional and energy needs. Unlike other eating disorders, ARFID is not driven by concerns about body shape or weight. Instead, the avoidance or restriction is based on sensory characteristics of food, fear of negative consequences (e.g., choking), or a lack of interest in eating.
Key Diagnostic Features
- Significant weight loss or failure to gain expected weight.
- Nutrient deficiencies or dependence on supplements.
- Interference with psychosocial functioning (e.g., missed school, limited family outings).
- Symptoms must not be better explained by another medical condition or mental disorder.
These criteria are outlined in the DSM5 and ICD11 and help clinicians distinguish ARFID from picky eating, food allergies, or other medical issues.
Common Causes and Triggers
ARFID can develop for several reasons, often overlapping:
- Sensory sensitivity: Intense dislike of texture, smell, color, or temperature.
- Fear of aversive consequences: History of choking, vomiting, or gastrointestinal pain.
- Lack of interest in eating: Low appetite, especially in children with neurodevelopmental disorders.
- Medical or developmental factors: Autism spectrum disorder, ADHD, gastrointestinal disorders, or early traumatic feeding experiences.
How ARFID Differs From Other Eating Disorders
While ARFID shares some features with anorexia nervosa or bulimia nervosa, key differences include:
- No preoccupation with body shape, weight, or thinness.
- Restriction is not a method of weight control.
- Symptoms may begin in early childhood rather than adolescence.
Understanding these distinctions is essential for appropriate treatment planning.
Potential Complications
If left untreated, ARFID can lead to serious medical and psychosocial outcomes:
- Growth failure or stunted height in children.
- Electrolyte imbalances, anemia, or osteoporosis.
- Social isolation and anxiety around meals.
- Increased risk of developing other eating disorders.
Quick Facts
- Prevalence estimates range from 15% in the general population, higher in clinical settings.
- Girls and boys are equally affected.
- Onset most frequently occurs before age 6, but ARFID can emerge at any age.
Assessment and Diagnosis
Professional evaluation typically includes:
- Comprehensive medical history and physical exam.
- Dietary recall and food frequency questionnaires.
- Screening tools such as the ARFIDQParent or the NineItem ARFID Screen.
- Psychological assessment to rule out comorbid anxiety, OCD, or autism.
Collaboration among pediatricians, dietitians, psychologists, and gastroenterologists yields the most accurate diagnosis.
Treatment Approaches
Effective treatment is multimodal and individualized:
1. Nutrition Intervention
- Gradual exposure to new foods using a hierarchy of tolerability.
- Caloric supplementation and, if needed, enteral nutrition.
- Education for families about balanced meals and nutrient requirements.
2. Psychological Therapy
- Cognitivebehavioral therapy (CBTARFID): Targets fearbased avoidance and sensory issues.
- Familybased treatment: Engages caregivers in structured mealtime routines.
- Mindfulness and anxietyreduction techniques.
3. Medical Management
- Treatment of underlying gastrointestinal problems (e.g., reflux, constipation).
- Monitoring of growth parameters and laboratory values.
- Medication for comorbid anxiety or obsessivecompulsive symptoms when indicated.
Early intervention improves outcomes, reducing the risk of longterm health problems.
Supporting Someone With ARFID
Family, friends, and educators can make a difference by:
- Creating a relaxed, pressurefree eating environment.
- Offering a variety of foods without forcing consumption.
- Celebrating small successes (e.g., trying a new texture).
- Seeking professional help at the first sign of persistent avoidance.
Resources
For further information and assistance:
References: DSM5 (American Psychiatric Association, 2013); ARFIDQParent validation studies, 20202022; NEDA clinical guidance, 2021.
